Loading clinical trials...
Loading clinical trials...
Use of Autologous Anti-CD22 CAR T Cells (CART22-65s) Co-administered With Humanized Anti-CD19 CAR T Cells (huCART19) in Children and Young Adults With Relapsed or Refractory B-ALL
Conditions
Interventions
Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s)
Autologous, humanized anti-CD19 CAR T cell therapy (huCART19)
Locations
1
United States
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
Start Date
January 25, 2023
Primary Completion Date
July 1, 2028
Completion Date
July 1, 2029
Last Updated
March 27, 2026
NCT07523555
NCT07223021
NCT07429461
NCT06785818
NCT06863259
NCT06580301
Lead Sponsor
Stephan Grupp MD PhD
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions